Darrell E. White, MD

It’s a mad, mad, mad world out there, folks.

We’re still in the first quarter of the insurance plan year.

’Twas a time, not so very long ago, when eye doctors treating dry eye disease had heart-to-hearts about how we should discuss the latency between onset of treatment and when patients would finally begin to feel some relief.

It seems as if eye doctors who treat the ocular surface and eyelids have been looking for a safe and effective treatment for the signs and symptoms of meibomian gland disease forever.

Brenting: v. To make bold and audacious deals in the eye care space.

For quite a few years now, we have been hearing the same stats about the prevalence and characteristics of dry eye disease patients in the U.S.

Over in my column The Dry Eye, I’ve embarked on a project to look at the basics of diagnosing and treating dry eye disease.

Anyone who has read any of my drivel knows that I am a long-time fan of testing tear osmolarity to guide the diagnosis and treatment of dry eye disease.

In a shocking display of “where ya been?” the Federal Trade Commission has “discovered” that pharmacy benefit managers drive up the cost of medications.

How many times have you seen a dry eye disease patient with little or no remaining clinical signs, only to learn that they are so stricken with photophobia that they’ve become nocturnal?